Czechowicz lab at Stanford Promising research needs continued support to answer the next question. A laboratory finding may need testing in more models. A screening study may need years of follow-up. An approach ready for a clinical study needs the...
Directory
Sudhir Borgonha
Translational Science Director | MD
Sudhir is a physician researcher with over 15 years of experience leading early stage projects and companies. Before coming to FARF, he was the Medical Director at Strand Genomics, where he was instrumental in developing customized gene panels in rare diseases and cancer, including launching a liquid biopsy test. He oversaw clinical reporting in collaboration with clinicians across the globe for over 5,000 patients per year, of which over a 1,000 were in rare diseases. As Translational Science Director, Sudhir leads development of FA translational science by working with academic and industry partners to pursue clinical research opportunities to better understand and treat FA. He manages translational projects including the development of a clinical registry and tissue bank.
A graduate of St. John’s Medical College, Bangalore and the Sloan School of Management, MIT, Sudhir is passionate about integrating emerging technologies into medicine. He is an aspiring writer and still has mixed feelings about why Bob Dylan won the Nobel prize in literature and Philip Roth didn’t.
The Latest
News & Events
How can we prevent cancer in people with FA? How can treatments become safer? At the 2026 FA Scientific Symposium in Phoenix, researchers shared progress toward answering these questions, alongside work to protect blood-forming cells and better understand the broader effects of FA. Some approaches are entering clinical studies. Others are helping researchers decide which ideas deserve further testing.
More than four decades ago, Lynn Frohnmayer was a mother searching for answers after learning that three of her five children had Fanconi anemia. There was no roadmap and no established network of families or experts. Information was scarce, treatments were limited, and the future her family had been given was devastating.